Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 143

1.

Screening of Chemopreventive Agents in Animal Models: Results on Reproducibility, Agents of a Given Class, and Agents Tested During Tumor Progression.

Lubet RA, Steele VE, Shoemaker RH, Grubbs CJ.

Cancer Prev Res (Phila). 2018 Jul 25. doi: 10.1158/1940-6207.CAPR-18-0084. [Epub ahead of print] Review.

PMID:
30045934
2.

Proteasome inhibition and mechanism of resistance to a synthetic, library-based hexapeptide.

Oerlemans R, Berkers CR, Assaraf YG, Scheffer GL, Peters GJ, Verbrugge SE, Cloos J, Slootstra J, Meloen RH, Shoemaker RH, Dijkmans BAC, Scheper RJ, Ovaa H, Jansen G.

Invest New Drugs. 2018 Oct;36(5):797-809. doi: 10.1007/s10637-018-0569-x. Epub 2018 Feb 14.

PMID:
29442210
3.

Immunoprevention of KRAS-driven lung adenocarcinoma by a multipeptide vaccine.

Pan J, Zhang Q, Sei S, Shoemaker RH, Lubet RA, Wang Y, You M.

Oncotarget. 2017 Aug 1;8(47):82689-82699. doi: 10.18632/oncotarget.19831. eCollection 2017 Oct 10.

4.

Targeting "Retired Antigens" for Cancer Immunoprevention.

Shoemaker RH, Forsthuber TG.

Cancer Prev Res (Phila). 2017 Nov;10(11):607-608. doi: 10.1158/1940-6207.CAPR-17-0188.

PMID:
29093010
5.

Identification of a nucleoside analog active against adenosine kinase-expressing plasma cell malignancies.

Nayar U, Sadek J, Reichel J, Hernandez-Hopkins D, Akar G, Barelli PJ, Sahai MA, Zhou H, Totonchy J, Jayabalan D, Niesvizky R, Guasparri I, Hassane D, Liu Y, Sei S, Shoemaker RH, Warren JD, Elemento O, Kaye KM, Cesarman E.

J Clin Invest. 2017 Jun 1;127(6):2066-2080. doi: 10.1172/JCI83936. Epub 2017 May 15.

6.

The National Cancer Institute's PREVENT Cancer Preclinical Drug Development Program: overview, current projects, animal models, agent development strategies, and molecular targets.

Shoemaker RH, Suen CS, Holmes CA, Fay JR, Steele VE.

Semin Oncol. 2016 Feb;43(1):189-197. doi: 10.1053/j.seminoncol.2015.09.008. Epub 2015 Sep 8. Review.

7.

Werner syndrome helicase has a critical role in DNA damage responses in the absence of a functional fanconi anemia pathway.

Aggarwal M, Banerjee T, Sommers JA, Iannascoli C, Pichierri P, Shoemaker RH, Brosh RM Jr.

Cancer Res. 2013 Sep 1;73(17):5497-507. doi: 10.1158/0008-5472.CAN-12-2975. Epub 2013 Jul 18.

8.

Identification of CBX3 and ABCA5 as putative biomarkers for tumor stem cells in osteosarcoma.

Saini V, Hose CD, Monks A, Nagashima K, Han B, Newton DL, Millione A, Shah J, Hollingshead MG, Hite KM, Burkett MW, Delosh RM, Silvers TE, Scudiero DA, Shoemaker RH.

PLoS One. 2012;7(8):e41401. doi: 10.1371/journal.pone.0041401. Epub 2012 Aug 3. Erratum in: PLoS One. 2012;7(11). doi:10.1371/annotation/8c74aaee-897d-4682-b62d-d95a3506c210.

9.

P6981, an arylstibonic acid, is a novel low nanomolar inhibitor of cAMP response element-binding protein binding to DNA.

Zhao J, Stagno JR, Varticovski L, Nimako E, Rishi V, McKinnon K, Akee R, Shoemaker RH, Ji X, Vinson C.

Mol Pharmacol. 2012 Nov;82(5):814-23. doi: 10.1124/mol.112.080820. Epub 2012 Jul 31.

10.

Discovery and preliminary SAR of bisbenzylisoquinoline alkaloids as inducers of C/EBPα.

Klausmeyer P, McCloud TG, Scudiero DA, Currens MJ, Cardellina Ii JH, Shoemaker RH.

Bioorg Med Chem. 2012 Aug 1;20(15):4646-52. doi: 10.1016/j.bmc.2012.06.017. Epub 2012 Jun 16.

11.

Impact of mutant β-catenin on ABCB1 expression and therapy response in colon cancer cells.

Stein U, Fleuter C, Siegel F, Smith J, Kopacek A, Scudiero DA, Hite KM, Schlag PM, Shoemaker RH, Walther W.

Br J Cancer. 2012 Apr 10;106(8):1395-405. doi: 10.1038/bjc.2012.81. Epub 2012 Mar 29.

12.

Substituted 3-(5-imidazo[2,1-b]thiazolylmethylene)-2-indolinones and analogues: synthesis, cytotoxic activity, and study of the mechanism of action.

Andreani A, Granaiola M, Locatelli A, Morigi R, Rambaldi M, Varoli L, Calonghi N, Cappadone C, Farruggia G, Stefanelli C, Masotti L, Nguyen TL, Hamel E, Shoemaker RH.

J Med Chem. 2012 Mar 8;55(5):2078-88. doi: 10.1021/jm2012694. Epub 2012 Feb 15.

13.

A pharmacologic inhibitor of the protease Taspase1 effectively inhibits breast and brain tumor growth.

Chen DY, Lee Y, Van Tine BA, Searleman AC, Westergard TD, Liu H, Tu HC, Takeda S, Dong Y, Piwnica-Worms DR, Oh KJ, Korsmeyer SJ, Hermone A, Gussio R, Shoemaker RH, Cheng EH, Hsieh JJ.

Cancer Res. 2012 Feb 1;72(3):736-46. doi: 10.1158/0008-5472.CAN-11-2584. Epub 2011 Dec 13.

14.

Structural characterization of inhibitor complexes with checkpoint kinase 2 (Chk2), a drug target for cancer therapy.

Lountos GT, Jobson AG, Tropea JE, Self CR, Zhang G, Pommier Y, Shoemaker RH, Waugh DS.

J Struct Biol. 2011 Dec;176(3):292-301. doi: 10.1016/j.jsb.2011.09.008. Epub 2011 Sep 22.

15.

X-ray structures of checkpoint kinase 2 in complex with inhibitors that target its gatekeeper-dependent hydrophobic pocket.

Lountos GT, Jobson AG, Tropea JE, Self CR, Zhang G, Pommier Y, Shoemaker RH, Waugh DS.

FEBS Lett. 2011 Oct 20;585(20):3245-9. doi: 10.1016/j.febslet.2011.08.050. Epub 2011 Sep 7.

16.

S100A4-induced cell motility and metastasis is restricted by the Wnt/β-catenin pathway inhibitor calcimycin in colon cancer cells.

Sack U, Walther W, Scudiero D, Selby M, Aumann J, Lemos C, Fichtner I, Schlag PM, Shoemaker RH, Stein U.

Mol Biol Cell. 2011 Sep;22(18):3344-54. doi: 10.1091/mbc.E10-09-0739. Epub 2011 Jul 27.

17.

Imidazo[2,1-b]thiazole guanylhydrazones as RSK2 inhibitors.

Andreani A, Granaiola M, Leoni A, Locatelli A, Morigi R, Rambaldi M, Varoli L, Lannigan D, Smith J, Scudiero D, Kondapaka S, Shoemaker RH.

Eur J Med Chem. 2011 Sep;46(9):4311-23. doi: 10.1016/j.ejmech.2011.07.001. Epub 2011 Jul 8.

PMID:
21794960
18.

CHEK2 genomic and proteomic analyses reveal genetic inactivation or endogenous activation across the 60 cell lines of the US National Cancer Institute.

Zoppoli G, Solier S, Reinhold WC, Liu H, Connelly JW Jr, Monks A, Shoemaker RH, Abaan OD, Davis SR, Meltzer PS, Doroshow JH, Pommier Y.

Oncogene. 2012 Jan 26;31(4):403-18. doi: 10.1038/onc.2011.283. Epub 2011 Jul 18. Erratum in: Oncogene. 2012 Jan 26;31(4):535-6.

PMID:
21765476
19.

Cysteine 81 is critical for the interaction of S100A4 and myosin-IIA.

Dulyaninova NG, Hite KM, Zencheck WD, Scudiero DA, Almo SC, Shoemaker RH, Bresnick AR.

Biochemistry. 2011 Aug 23;50(33):7218-27. doi: 10.1021/bi200853y. Epub 2011 Jul 21.

20.

Novel effect of antihelminthic Niclosamide on S100A4-mediated metastatic progression in colon cancer.

Sack U, Walther W, Scudiero D, Selby M, Kobelt D, Lemm M, Fichtner I, Schlag PM, Shoemaker RH, Stein U.

J Natl Cancer Inst. 2011 Jul 6;103(13):1018-36. doi: 10.1093/jnci/djr190. Epub 2011 Jun 17.

PMID:
21685359
21.

ASPS-1, a novel cell line manifesting key features of alveolar soft part sarcoma.

Kenney S, Vistica DT, Stockwin LH, Burkett S, Hollingshead MG, Borgel SD, Butcher DO, Schrump DS, Shoemaker RH.

J Pediatr Hematol Oncol. 2011 Jul;33(5):360-8. doi: 10.1097/MPH.0b013e3182002f9f.

PMID:
21552147
22.

Intervening in β-catenin signaling by sulindac inhibits S100A4-dependent colon cancer metastasis.

Stein U, Arlt F, Smith J, Sack U, Herrmann P, Walther W, Lemm M, Fichtner I, Shoemaker RH, Schlag PM.

Neoplasia. 2011 Feb;13(2):131-44.

23.

Inhibition of helicase activity by a small molecule impairs Werner syndrome helicase (WRN) function in the cellular response to DNA damage or replication stress.

Aggarwal M, Sommers JA, Shoemaker RH, Brosh RM Jr.

Proc Natl Acad Sci U S A. 2011 Jan 25;108(4):1525-30. doi: 10.1073/pnas.1006423108. Epub 2011 Jan 10.

24.

Substituted E-3-(3-indolylmethylene)-1,3-dihydroindol-2-ones with antitumor activity. In depth study of the effect on growth of breast cancer cells.

Andreani A, Bellini S, Burnelli S, Granaiola M, Leoni A, Locatelli A, Morigi R, Rambaldi M, Varoli L, Calonghi N, Cappadone C, Zini M, Stefanelli C, Masotti L, Shoemaker RH.

J Med Chem. 2010 Aug 12;53(15):5567-75. doi: 10.1021/jm1007165.

25.

Adaphostin toxicity in a sensitive non-small cell lung cancer model is mediated through Nrf2 signaling and heme oxygenase 1.

Fer ND, Shoemaker RH, Monks A.

J Exp Clin Cancer Res. 2010 Jul 9;29:91. doi: 10.1186/1756-9966-29-91.

26.

Antitumor activity and COMPARE analysis of bis-indole derivatives.

Andreani A, Burnelli S, Granaiola M, Leoni A, Locatelli A, Morigi R, Rambaldi M, Varoli L, Landi L, Prata C, Dalla Sega FV, Caliceti C, Shoemaker RH.

Bioorg Med Chem. 2010 May 1;18(9):3004-11. doi: 10.1016/j.bmc.2010.03.063. Epub 2010 Mar 28.

PMID:
20395150
27.

The arylstibonic acid compound NSC13746 disrupts B-ZIP binding to DNA in living cells.

Heyerdahl SL, Rozenberg J, Jamtgaard L, Rishi V, Varticovski L, Akah K, Scudiero D, Shoemaker RH, Karpova TS, Day RN, McNally JG, Vinson C.

Eur J Cell Biol. 2010 Jul;89(7):564-73. doi: 10.1016/j.ejcb.2009.11.029. Epub 2010 Apr 1.

PMID:
20362353
28.

Complex display of putative tumor stem cell markers in the NCI60 tumor cell line panel.

Stuelten CH, Mertins SD, Busch JI, Gowens M, Scudiero DA, Burkett MW, Hite KM, Alley M, Hollingshead M, Shoemaker RH, Niederhuber JE.

Stem Cells. 2010 Apr;28(4):649-60. doi: 10.1002/stem.324.

29.

12 Arylstibonic acids that inhibit the DNA binding of five B-ZIP dimers.

Rishi V, Oh WJ, Heyerdahl SL, Zhao J, Scudiero D, Shoemaker RH, Vinson C.

J Struct Biol. 2010 May;170(2):216-25. doi: 10.1016/j.jsb.2010.02.013. Epub 2010 Feb 20.

PMID:
20176111
30.

Identification of bona fide esophageal adenocarcinoma cell lines.

Shoemaker RH.

J Natl Cancer Inst. 2010 Feb 24;102(4):212-3. doi: 10.1093/jnci/djp526. Epub 2010 Jan 14. No abstract available.

PMID:
20075369
31.

RSK2 Binding Models Delineate Key Features for Activity.

Gussio R, Currens MJ, Scudiero DA, Smith JA, Lannigan DA, Shoemaker RH, Zaharevitz DW, Nguyen TL.

J Chem Pharm Res. 2010;2(5):587-598.

32.

Antiangiogenic agents and HIF-1 inhibitors meet at the crossroads.

Rapisarda A, Shoemaker RH, Melillo G.

Cell Cycle. 2009 Dec 15;8(24):4040-3. Epub 2009 Dec 21.

PMID:
19923892
33.

Potential for therapeutic targeting of tumor stem cells.

Saini V, Shoemaker RH.

Cancer Sci. 2010 Jan;101(1):16-21. doi: 10.1111/j.1349-7006.2009.01371.x. Epub 2009 Sep 22. Review.

34.

Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide].

Jobson AG, Lountos GT, Lorenzi PL, Llamas J, Connelly J, Cerna D, Tropea JE, Onda A, Zoppoli G, Kondapaka S, Zhang G, Caplen NJ, Cardellina JH 2nd, Yoo SS, Monks A, Self C, Waugh DS, Shoemaker RH, Pommier Y.

J Pharmacol Exp Ther. 2009 Dec;331(3):816-26. doi: 10.1124/jpet.109.154997. Epub 2009 Sep 9.

35.

Therapeutic vulnerability of an in vivo model of alveolar soft part sarcoma (ASPS) to antiangiogenic therapy.

Vistica DT, Hollingshead M, Borgel SD, Kenney S, Stockwin LH, Raffeld M, Schrump DS, Burkett S, Stone G, Butcher DO, Shoemaker RH.

J Pediatr Hematol Oncol. 2009 Aug;31(8):561-70. doi: 10.1097/MPH.0b013e3181a6e043.

36.

Gene expression-signature of belinostat in cell lines is specific for histone deacetylase inhibitor treatment, with a corresponding signature in xenografts.

Monks A, Hose CD, Pezzoli P, Kondapaka S, Vansant G, Petersen KD, Sehested M, Monforte J, Shoemaker RH.

Anticancer Drugs. 2009 Sep;20(8):682-92. doi: 10.1097/CAD.0b013e32832e14e1.

PMID:
19606018
37.

Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells.

Sei S, Mussio JK, Yang QE, Nagashima K, Parchment RE, Coffey MC, Shoemaker RH, Tomaszewski JE.

Mol Cancer. 2009 Jul 14;8:47. doi: 10.1186/1476-4598-8-47.

38.

Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition.

Rapisarda A, Hollingshead M, Uranchimeg B, Bonomi CA, Borgel SD, Carter JP, Gehrs B, Raffeld M, Kinders RJ, Parchment R, Anver MR, Shoemaker RH, Melillo G.

Mol Cancer Ther. 2009 Jul;8(7):1867-77. doi: 10.1158/1535-7163.MCT-09-0274. Epub 2009 Jul 7.

39.

Cytotoxic and HIF-1alpha inhibitory compounds from Crossosoma bigelovii.

Klausmeyer P, Zhou Q, Scudiero DA, Uranchimeg B, Melillo G, Cardellina JH, Shoemaker RH, Chang CJ, McCloud TG.

J Nat Prod. 2009 May 22;72(5):805-12. doi: 10.1021/np8006342.

PMID:
19405508
40.

Crystal structure of checkpoint kinase 2 in complex with NSC 109555, a potent and selective inhibitor.

Lountos GT, Tropea JE, Zhang D, Jobson AG, Pommier Y, Shoemaker RH, Waugh DS.

Protein Sci. 2009 Jan;18(1):92-100. doi: 10.1002/pro.16.

41.

Gene expression profiling of alveolar soft-part sarcoma (ASPS).

Stockwin LH, Vistica DT, Kenney S, Schrump DS, Butcher DO, Raffeld M, Shoemaker RH.

BMC Cancer. 2009 Jan 15;9:22. doi: 10.1186/1471-2407-9-22.

42.

Inhibitors of the NF-kappaB activation pathway from Cryptocarya rugulosa.

Meragelman TL, Scudiero DA, Davis RE, Staudt LM, McCloud TG, Cardellina JH 2nd, Shoemaker RH.

J Nat Prod. 2009 Mar 27;72(3):336-9. doi: 10.1021/np800350x.

PMID:
19093800
43.

Antitumor activity of new substituted 3-(5-imidazo[2,1-b]thiazolylmethylene)-2-indolinones and 3-(5-imidazo[2,1-b]thiadiazolylmethylene)-2-indolinones: selectivity against colon tumor cells and effect on cell cycle-related events.

Andreani A, Burnelli S, Granaiola M, Leoni A, Locatelli A, Morigi R, Rambaldi M, Varoli L, Calonghi N, Cappadone C, Voltattorni M, Zini M, Stefanelli C, Masotti L, Shoemaker RH.

J Med Chem. 2008 Dec 11;51(23):7508-13. doi: 10.1021/jm800827q.

PMID:
19006285
44.

Induction of apoptosis in human cancer cells by candidaspongiolide, a novel sponge polyketide.

Trisciuoglio D, Uranchimeg B, Cardellina JH, Meragelman TL, Matsunaga S, Fusetani N, Del Bufalo D, Shoemaker RH, Melillo G.

J Natl Cancer Inst. 2008 Sep 3;100(17):1233-46. doi: 10.1093/jnci/djn239. Epub 2008 Aug 26.

45.

Identification of polymerase and processivity inhibitors of vaccinia DNA synthesis using a stepwise screening approach.

Silverman JE, Ciustea M, Shudofsky AM, Bender F, Shoemaker RH, Ricciardi RP.

Antiviral Res. 2008 Nov;80(2):114-23. doi: 10.1016/j.antiviral.2008.05.010. Epub 2008 Jun 20.

46.

Separation and SAR study of HIF-1alpha inhibitory tubulosines from Alangium cf. longiflorum.

Klausmeyer P, McCloud TG, Uranchimeg B, Melillo G, Scudiero DA, Cardellina JH 2nd, Shoemaker RH.

Planta Med. 2008 Feb;74(3):258-63. doi: 10.1055/s-2008-1034315. Epub 2008 Feb 26.

PMID:
18302092
47.

New antitumor imidazo[2,1-b]thiazole guanylhydrazones and analogues.

Andreani A, Burnelli S, Granaiola M, Leoni A, Locatelli A, Morigi R, Rambaldi M, Varoli L, Calonghi N, Cappadone C, Farruggia G, Zini M, Stefanelli C, Masotti L, Radin NS, Shoemaker RH.

J Med Chem. 2008 Feb 28;51(4):809-16. doi: 10.1021/jm701246g. Epub 2008 Feb 6.

PMID:
18251494
48.

Immunohistochemical discrimination between the ASPL-TFE3 fusion proteins of alveolar soft part sarcoma.

Vistica DT, Krosky PM, Kenney S, Raffeld M, Shoemaker RH.

J Pediatr Hematol Oncol. 2008 Jan;30(1):46-52. doi: 10.1097/MPH.0b013e31815d1d6f.

PMID:
18176180
49.

Differential involvement of vascular endothelial growth factor in the survival of hypoxic colon cancer cells.

Calvani M, Trisciuoglio D, Bergamaschi C, Shoemaker RH, Melillo G.

Cancer Res. 2008 Jan 1;68(1):285-91. doi: 10.1158/0008-5472.CAN-07-5564.

50.

Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo.

Gills JJ, Lopiccolo J, Tsurutani J, Shoemaker RH, Best CJ, Abu-Asab MS, Borojerdi J, Warfel NA, Gardner ER, Danish M, Hollander MC, Kawabata S, Tsokos M, Figg WD, Steeg PS, Dennis PA.

Clin Cancer Res. 2007 Sep 1;13(17):5183-94.

Supplemental Content

Loading ...
Support Center